ClinicalTrials.gg
RecruitingNCT06075485KEOPSUpdated Nov 16, 2026

Management of Drug-resistant Epilepsy in Infants and Children: a Real-life Study of the Use of the Ketogenic Diet in France and the KetoCal® Range in Its Maintenance

An observational study in Drug Resistant Epilepsy and Ketogenic Dieting, sponsored by Nutricia Nutrition Clinique. Recruiting at 1 site in France. Open to participants aged 5 Months to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Nutricia Nutrition Clinique (part of Danone) · Observational

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.
Updated Nov 16, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
133
Ages
5 Months to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Drug Resistant Epilepsy with a site in France — 16 open to participants now, 17 under way, 1 of them phase 3. Drug Resistant Epilepsy · France.

Planned enrollment
4th of 11
133 · median 110
Started
2024
with 6 others
Observational
11 of 35
6 open now
Primary completion
2027-06
later than 8 of 16 live
Registered
25th of 35
by date

Among the 35 studies in Drug Resistant Epilepsy with a site in France, this one is the 4th largest by planned enrollment of the 11 observational ones that give a count, is one of 7 that started in 2024, is one of 11 observational ones, reaches primary completion later than 8 of the 16 other live ones, and was the 25th registered.

Drug Resistant Epilepsy

258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.

Browse Drug Resistant Epilepsy studies →

Open to participants now

16 of the 35 studies in Drug Resistant Epilepsy with a site in France are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 68 Drug Resistant Epilepsy studies recruiting now, 27 (40%) set no upper age limit and 40 (59%) stop at 75 or younger; 27 take children under 18; 6 take healthy volunteers.

This study: 5 Months to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Drug Resistant Epilepsy with a site in France, or all of them as a file.
02

Study summary

This is a multicenter, prospective, observational, longitudinal study designed to describe the therapeutic value of the KetoCal® range in the maintenance of a ketogenic diet during the management of infants (from 5 months) and children up to 17 years of age (i.e. 18 years minus 1 day) with drug-resistant epilepsy.

This study is being conducted according to standard medical practice. No change in diagnostic or therapeutic management habits is imposed by this study. Quality of life questionnaires are the only additional procedures for this research.

Read the detailed description

NUTRICIA has developed the KetoCal® range (4:1 and 3:1), a food for special medical purposes (DADFMS), to help healthcare professionals and patients establish and maintain a CR. KetoCal® 4:1 features a 4:1 ratio of fat to (carbohydrate + protein), while containing vitamins, minerals, trace elements and fiber. Similarly, KetoCal® 3:1 has a 3:1 ratio of lipids / (carbohydrates + proteins), while containing vitamins, minerals, trace elements and fiber. The KetoCal® range can be consumed orally, as a drink after dilution in hot water, incorporated as an ingredient in a recipe or administered by enteral feeding tube.

The KEOPS study is designed to gather real-life data on the therapeutic value of using the KetoCal® range in the management of drug-resistant epilepsy in infants (from 5 months) and children up to 18 years of age. Patients will be managed according to standard care practices. Initiation of ketogenic dieting will be at the investigator's discretion during the child's hospitalization.

03

Conditions studied

  • Drug Resistant Epilepsy
  • Ketogenic Dieting

Keywords

  • ketogenic diet
  • epilepsy
  • drug resistance
04

Who can participate

Ages eligible
5 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A total of 133 eligible patients will be recruited in this project. The target population of our project will be infants (from 5 months of age) and children up to 18 years of age treated for drug-resistant epilepsy, who, depending on the physician in charge of the patient, may benefit from the initiation of a KetoCal® 3:1 or 4:1 CR, depending on the child's age.

We exclude from our study protected legal representatives of minors (under guardianship, curatorship, minor parents). In addition, people taking part in this study will not be able to take part in any other interventional or observational research for the duration of the study. A 6-month exclusion period is planned as part of this project.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants from 5 months and children up to 17 years of age (maximum 18 years minus 1 day).
  • With drug-resistant epilepsy according to ILAE (International League Against Epilepsy) criteria: persistence of epileptic seizures after failure of two appropriate antiepileptic drugs tried consecutively or in well-tolerated combination.
  • Indication for CR by a physician.
  • Parents (or legal guardians) able to set up and follow the diet, assessed during a joint doctor-dietician consultation.
  • Written authorization from one (or both) parents or the child's legal representative to collect personal information about their child.
  • Affiliation of the infant/child with the social security system.

Exclusion criteria

Exclusion Criteria:

  • to ketogenic diet at initial assessment.
  • Children already on a ketogenic diet.
  • Parenteral nutrition.
  • Concurrent prescription of other foodstuffs intended for special medical purposes (DADFMS) such as KetoVie or Keyo.
  • Protected legal representative (under legal protection, or deprived of liberty by judicial or administrative decision).
  • Legal representative not covered by a social security scheme.
  • Legal representative unable to understand study protocol.

Ancillary study eligibility criteria :

  • Patients included in the study.
  • Continued on the ketogenic diet for at least 2 months.
  • Having consented to participate in the ancillary study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
133 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patient

    Infants (from 5 months) and children up to 17 years of age follow up for drug resistant epilepsy

    Other: Ketocal

Interventions

  • OtherKetocal

    ketogene diet

06

What researchers measure

Primary outcomes

  1. Description of compliance

    Retention rate which is defined as the proportion of patients who have continued KD for up to 6 months.

    Time frame: 6 months

Secondary outcomes

  1. Duration of compliance

    Describe the duration of KD compliance.

    Time frame: From Month 1 to Month 6

  2. Efficacy of KD

    Describe the efficacy of KD. Efficacy is defined as responders to KD with seizure frequency reduced by more than 50%, or no seizure frequency in the case of total response to CR in the last week.

    Time frame: From Month 1 to Month 6

  3. KD tolerance.

    Describe KD tolerance as a number of AE reported

    Time frame: From inclusion to Month 6

  4. QoL evolution

    Describe changes in patients' quality of life following initiation of KD at inclusion, and M6; using PedsQL ™ questionnaires

    Time frame: From inclusion to Month 6

  5. Influence of KD

    Total number of antiepileptic drugs used for each child including their current treatment until the end of the study.

    Time frame: From inclusion to Month 6

  6. Ketosis achievement

    Evaluate the time it takes to achieve ketosis. Ketosis will be assessed by ketonuria or ketonemia, depending on the habits of each center.

    Time frame: From inclusion to Month 6

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2024 (actual). Primary completion is estimated for Jun 2027, 41 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Jun 2026 → Jun 2027 and completion Jun 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2023
First posted
Oct 10, 2023
StartActual
Jan 15, 2024
Primary completionEst.
Jun 2027was Jun 2026
CompletionEst.
Jun 2027was Jun 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2026→Jun 2027
Nov 16, 2026
Study completion
Jun 2026→Jun 2027
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Primary completion Jun 2026→Jun 2027
    Study completion Jun 2026→Jun 2027
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06075485
Collaborators
Euraxi Pharma
Responsible party
Sponsor
First posted
Oct 10, 2023
Start date
Jan 15, 2024
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Elmire DEGOUL-COMBESCOT, PhD
Contact
Elmire.DEGOUL@danone.com
+33 (0) 6 27 91 97 08

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion